MDNA 413

Drug Profile

MDNA 413

Alternative Names: MDNA413

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics; Stanford University
  • Class Antineoplastics; Cytokines; Interleukins; Recombinant fusion proteins; Small molecules
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Atopic dermatitis; Solid tumours

Most Recent Events

  • 16 Mar 2017 Medicenna Therapeutics enter into a sponsored research agreement with the University of Texas MD Anderson Cancer Center to develop fusion protein therapeutics targeting the IL 4 receptor and to advance preclinical development of Empowered Cytokines™ based on IL 4 and IL 13 Superkine™ platform
  • 02 Mar 2017 Medicenna Therapeutics Inc. has been acquired by Medicenna Therapeutics Corp
  • 15 Dec 2016 Preclinical trials in Solid tumours, Atopic dermatitis and Asthma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top